Research map: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

Back to the article

Papers in this map

  1. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells · Daniel W. Lee · 2018 · 3668 citations · Cited by this paper
  2. Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors · Jiacheng Lou · 2026 · Cites this paper
  3. Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial · 2026 · Related
  4. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma · Shaji Kunnathu Kumar · 2016 · 3108 citations · Cited by this paper
  5. Treatment Decisions in Multiple Myeloma · Tarek H. Mouhieddine · 2026 · Cites this paper
  6. Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial · 2026 · Related
  7. Teclistamab in Relapsed or Refractory Multiple Myeloma · Philippe Moreau · 2022 · 1248 citations · Cited by this paper
  8. Infection prevention and management in patients with multiple myeloma treated with bispecific antibodies: a case-based approach for routine clinical practice · Lorenzo Cani · 2026 · Cites this paper
  9. Data rights are the missing pillar for modernizing consent in medicine · 2026 · Related
  10. Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma · Ajai Chari · 2022 · 725 citations · Cited by this paper
  11. Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection · 2026 · Related
  12. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results · Alexander M. Lesokhin · 2023 · 640 citations · Cited by this paper
  13. Multi-omics maps human–pig interactions in extracorporeal liver cross-circulation · 2026 · Related
  14. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma · Holly Lee · 2023 · 356 citations · Cited by this paper
  15. Oligonucleotide–siRNA conjugate for SOD1 amyotrophic lateral sclerosis: a phase 1 trial · 2026 · Related
  16. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals · Nora Philipp · 2022 · 283 citations · Cited by this paper
  17. The genetic architecture of fibromyalgia across 2.5 million individuals · 2026 · Related
  18. Proposed guidelines for diagnosing chronic active Epstein‐Barr virus infection · Motohiko Okano · 2005 · 276 citations · Cited by this paper
  19. Individualized antisense oligonucleotides for SCN2A-related developmental epileptic encephalopathy · 2026 · Related
  20. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel · Noopur S Raje · 2023 · 201 citations · Cited by this paper
  21. Early detection of Alzheimer’s disease with circular RNA from blood · 2026 · Related
  22. Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia · Andrew G. Polson · 2006 · 141 citations · Cited by this paper
  23. When caution becomes harm · 2026 · Related
  24. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy · Christopher James Ferreri · 2023 · 121 citations · Cited by this paper
  25. FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma · Kristi Elkins · 2012 · 95 citations · Cited by this paper
  26. T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma · Christie P.M. Verkleij · 2024 · 72 citations · Cited by this paper
  27. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma · Tomoko Ise · 2006 · 68 citations · Cited by this paper
  28. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies · Cyrille Touzeau · 2024 · 67 citations · Cited by this paper
  29. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma · A. Keith Stewart · 2019 · 63 citations · Cited by this paper
  30. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma · Dongpeng Jiang · 2023 · 42 citations · Cited by this paper
  31. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study · Carlyn Rose C. Tan · 2025 · 41 citations · Cited by this paper
  32. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis) · María‐Victoria Mateos · 2024 · 37 citations · Cited by this paper
  33. Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium · Danai Dima · 2024 · 9 citations · Cited by this paper
  34. Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B · Simon Harrison · 2025 · 9 citations · Cited by this paper
  35. Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial · Adam D. Cohen · 2025 · 8 citations · Cited by this paper
  36. Untitled · Cited by this paper
  37. Untitled · Cited by this paper
  38. Untitled · Cited by this paper
  39. Untitled · Cited by this paper

Source: OpenAlex (CC0)